"Exports will decline, but the strong yen will reduce import costs and boost corporate earnings," said Atsushi Takeda, chief economist at Itochu Research Institute. "And the suppression of ...

Harmony Biosciences Holdings, Inc. ( NASDAQ: HRMY) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executive Officer Adam ...

Past collaborations included Takeda, Sanofi Bristol Myers Squibb ... comfortable financial position for an early-stage drug discovery company, with $625M in Q3 2022, for a net cash burn of just $15M.

These programs are developed in partnership with Pfizer, Novartis, Biogen, and Takeda. The company has invested heavily ... In the last quarter (Q3 2022), the company had $62M in current assets. Net ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R&D pipeline in the process. The two terminations, coupled to the ...

Investors might want to bet on Takeda Pharmaceutical Co. (TAK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a potential "inflection point" for the company. President Donald Trump is ...

NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts.